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requested laboratory investigations in both primary and secondary
care. Fortunately, most TFTs are straightforward to interpret and
conﬁrm the clinical impression of euthyroidism, hypothyroidism
or hyperthyroidism. However, in an important subgroup of pa-
tients the results of TFTs can seem confusing, either by virtue of
being discordant with the clinical picture or because they appear
incongruent with each other [e.g. raised thyroid hormones (TH),
but with non-suppressed thyrotropin (TSH); raised TSH, but with
normal TH]. In such cases, it is important ﬁrst to revisit the clinical
context, and to consider potential confounding factors, including
alterations in normal physiology (e.g. pregnancy), intercurrent
(non-thyroidal) illness, and medication usage (e.g. thyroxine,
amiodarone, heparin). Once these have been excluded, laboratory
artefacts in commonly used TSH or TH immunoassays should be
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remainder, consideration should be given to screening for rare
genetic and acquired disorders of the hypothalamic–pituitary–
thyroid (HPT) axis [e.g. resistance to thyroid hormone (RTH), thy-
rotropinoma (TSHoma)]. Here, we discuss the main pitfalls in the
measurement and interpretation of TFTs, and propose a structured
algorithm for the investigation and management of patients with
anomalous/discordant TFTs.
 2013 The Authors. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Introduction
Although thyroid disease in its most ﬂorid forms is easily recognised, minor perturbations of
thyroid status can be more difﬁcult to diagnose clinically, manifesting symptoms and/or signs that
are non-speciﬁc (e.g. tiredness/lethargy; weight gain/loss; palpitations), and typically presenting
to clinicians other than endocrinologists. Conﬁrmation or exclusion of an underlying thyroid
disorder therefore requires a high clinical index of suspicion, coupled with accurate measurement
and interpretation of thyroid hormone (TH) and thyrotropin (TSH) concentrations. In the majority
of cases, the results of thyroid function tests (TFTs) are straightforward, presenting a pattern that is
readily recognised and consistent with the clinical impression of thyroid status. However, in a
small, but signiﬁcant subgroup of patients, the interpretation of TFTs is more challenging, either
because the results appear discordant with the clinical picture (e.g. normal TSH in a patient with
suspected thyrotoxicosis), or because different measurements appear to contradict each other (e.g.
raised TH concentrations, but with non-suppressed TSH). In these patients, a structured approach
to further investigation is required if resources are not to be wasted and inappropriate treatment
recommended. In most instances, careful clinical reassessment of thyroid status, together with
considering possible confounding factors [e.g. pregnancy, intercurrent (non-thyroidal) illness, drug
therapy] readily identiﬁes the cause of apparently anomalous/discordant TFTs. Where this is not
the case, interference in one or other of TH (T4, thyroxine; T3, triiodothyronine) or TSH assays
should be systematically screened for, and may require specialist laboratory work up. Thereafter,
rare genetic and acquired disorders of hypothalamic–pituitary–thyroid (HPT) axis function should
be considered, and referral to a specialist endocrine unit is advised. In this article we highlight the
various pitfalls that can befall a clinician when faced with apparently anomalous or discordant
TFTs, and show how a structured clinical approach, combined with judicious use of biochemical,
radiological and genetic investigations, enables the cause of apparently confusing TFTs to be
readily resolved in most cases.
General considerations when interpreting TFTs
A sound knowledge of hypothalamic–pituitary–thyroid axis physiology and the factors governing
TH action at a tissue/cellular level, coupled with an understanding of the diverse array of congenital
and acquired conditions that can manifest with different TFT patterns, is crucial to establishing the
correct diagnosis in patients presenting with anomalous TFTs.HPT axis physiology and TH action
TH production is tightly regulated by hypothalamic thyrotropin releasing hormone (TRH) and
pituitary TSH (Fig. 1). In any given individual T4 and T3 concentrations remain relatively constant
throughout life, and reﬂect the ‘set-point’ of the hypothalamic–pituitary–thyroid (HPT) axis in that
individual [1]. In the euthyroid state, the thyroid gland secretes 85–90% T4 and 10–15% T3, both of
which are heavily (>99.5%) protein bound to thyroxine binding globulin (TBG), albumin and
transthyretin (prealbumin). Cellular entry of TH in many tissues (e.g. the brain) is dependent on
speciﬁc membrane proteins [e.g. monocarboxylate transporter 8 (MCT8)] [2] (Fig. 1). These
Fig. 1. Schematic representation of the hypothalamic–pituitary–thyroid axis and the various factors governing thyroid hormone
transport, metabolism and action at the tissue/cellular level. Key: a1, TRa1; b1, TRb1; b2, TRb2; CoA, coactivator; DNA, deoxy-
ribonucleic acid; MCT8, monocarboxylate transporter 8; RXR, retinoid X receptor; SA, somatostatin; T3, triiodothyronine; T4,
thyroxine; TR, thyroid receptor; TRE, thyroid response element; TRH, thyrotropin releasing hormone; TSH, thyroid stimulating
hormone (thyrotropin).
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balance between secreted T4 and T3) [3]. A further tier of regulation of TH action is provided at a
pre-receptor level by a family of intracellular deiodinases (DIOs): hepatic type 1 DIO mediates pe-
ripheral T4 to T3 conversion; DIO2 converts T4 to T3 in the hypothalamus and pituitary, thereby
playing a central role in negative feedback regulation of the HPT axis; in contrast DIO3 converts T4 to
reverse T3 (rT3) and T3 to T2, thereby limiting TH action [4] (Fig. 1). T3 is the principal bioactive
hormone and although non-genomic effects of TH are recognised [5], its major actions are mediated
by binding to a receptor (TR) in the nucleus of target cells (Fig. 1). Two thyroid hormone receptor
genes (THRA, THRB) exist on chromosomes 17 and 3 respectively. Each gene undergoes alternate
splicing to generate TRa1, TRa2, TRb1 and TRb2 isoforms, each with differing tissue distributions
(e.g. TRa1 is the predominant isoform in the central nervous system, myocardium, colon and skeletal
muscle; TRb1 is highly expressed in the liver and kidney; TRb2 plays a major role in negative
feedback regulation at the level of the hypothalamus and pituitary) [6]. Interestingly, TRa2 is non-
hormone binding and its role in normal physiology remains unclear, although it may serve as a
natural antagonist of TRa1 action. TRs bind to speciﬁc recognition sequences (thyroid hormone
response elements, TREs) in the promoter or other regulatory regions of TH target genes, and
typically exert opposing effects depending on whether the receptor is occupied by ligand (T3) or not
[7]. For example, on a positively regulated target gene (e.g. hepatic sex hormone binding globulin)
unliganded TR recruits a repression complex [including corepressors such as NCoR (nuclear receptor
corepressor) and SMRT (silencing mediator of retinoic acid and thyroid receptors)] that suppresses
gene transcription. In contrast, following T3 binding, TR undergoes a conformational change that
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thus enhancing target gene transcription (Fig. 1). In this way TR is able to function as a molecular
switch. Interestingly, T3 binding to TR has opposite effects on negatively regulated target genes (e.g.
TRH, TSHa and TSHb gene promoters) [7].
Changes in thyroid status are normally associated with concordant changes in TH and TSH con-
centrations (e.g. raised T4 and T3 with suppressed TSH in thyrotoxicosis; low T4 and T3 with elevated
TSH in hypothyroidism). However, the population reference ranges for TH are relatively broad – in
contrast to the narrow individual variations of serum TH seen in normal subjects [1]. As a result,
changes in TH concentrations sufﬁcient to render a subject hypo- or hyper-thyroid may not necessarily
be associated with numerically abnormal T4 or T3 concentrations (as occurs in so-called ‘subclinical’
hypo- or hyper-thyroidism). Accordingly, TSH has been recommended as a frontline screening test for
thyroid dysfunction, as relatively modest changes in TH concentrations are associated with marked
excursions in TSH. However, screening exclusively with TSH will result in misdiagnosis of some cases,
whilst other conditions may be missed altogether (by virtue of returning a TSH result that falls within
the reference range despite overt hypothalamic–pituitary–thyroid dysfunction) (Table 1). Accordingly,
many laboratories now routinely offer combination screening with both T4 and TSHmeasurement. It is
also important to bear in mind whether total (TT4, TT3) or free (FT4, FT3) TH are measured, as changes
in circulating binding proteins (e.g. elevated TBG in pregnancy) can seriously confound interpretation
of TT4 and TT3 concentrations (see below).
Given the complexity of pathways that govern TH action at tissue and cellular levels, it is not sur-
prising that some patients receiving exogenous thyroid hormone replacement therapy report on-going
symptoms despite optimal thyroid function tests (e.g. normal T4 and T3 with TSH <2 mU/L in primary
hypothyroidism). In some of these it is conceivable that restoring euthyroidism in the HPTaxis does not
equate with resolution of hypothyroidism in other target tissues. For these individuals, and for patients
with central hypothyroidism where TSH is not a reliable indicator, better tissue markers of TH action
are required to help guide TH replacement strategies.
TFT patterns and their aetiology
When interpreting TFTs it is helpful to keep in mind the seven major patterns that may be
encountered and the conditions/circumstances in which these can arise (Fig. 2). Decisions on whether
to initiate further investigations or the choice of laboratory, radiological and genetic tests to pursue, can
then be focused with a view to conﬁrming or excluding speciﬁc diagnoses.
Speciﬁc considerations when interpreting TFTs
Clinical context/thyroid status
As a general rule, thyroid function tests should only be requested when there are speciﬁc clinical
features that require a primary disorder of hypothalamic–pituitary–thyroid function to be ascertained.
Measuring TH and/or TSH concentrations when there is a low index of suspicion for HPT dysfunction
risks the possibility of TFTs that confound, and a train of inappropriate investigations andmanagement
(e.g. in non-thyroidal illness). Accordingly, when apparently anomalous TFTs occur, the ﬁrst step is toTable 1
Conditions in which measurement of TSH alone may be misleading.
 Recent treatment for thyrotoxicosis (TSH may remain suppressed even when TH concentrations have normalised)
 Non-thyroidal illness
 TSH assay interference
 Central hypothyroidism (e.g. hypothalamic/pituitary disorders)
 TSH-secreting pituitary adenoma (thyrotropinoma/TSHoma)
 Resistance to thyroid hormone (RTH)
 Disorders of thyroid hormone transport or metabolism
Key: TH, thyroid hormone; TSH, thyroid-stimulating hormone/thyrotropin.
Fig. 2. Different patterns of thyroid function tests and their causes. Key: ATDs, antithyroid drugs; FDH, familial dysalbuminaemic
hyperthyroxinaemia; FT4, free thyroxine; FT3, free triiodothyronine; NTI, non-thyroidal illness; TKIs, tyrosine kinase inhibitors; TSH,
thyroid-stimulating hormone/thyrotropin [*signiﬁes that TSH may be either fully suppressed (for example as seen in classical pri-
mary hyperthyroidism) or partially suppressed (i.e. measurable, but below the lower limit of normal)]. Reproduced with permission
from: Koulouri O, Gurnell M. How to interpret thyroid function tests. Clin Med 2013; 13:282–6. Copyright  2013 Royal College of
Physicians.
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Importantly, many clinical laboratories provide generic reference ranges for T4, T3 and TSH, despite
increasing evidence that this may not be appropriate, with, for example, ethnicity, iodine intake,
gender, age, and body mass index inﬂuencing the reference range of serum TSH [8,9], while pregnancy
is associated with major changes in both TH and TSH concentrations [10].Non-thyroidal illness
A common pitfall in the interpretation of thyroid function tests is to overlook the confounding
effects of ‘non-thyroidal illness’ (NTI). NTI (or sick euthyroid syndrome) is a relatively common ﬁnding
following any acute or chronic illness, and is deﬁned by the absence of an intrinsic abnormality of HPT
function – rather it is considered a secondary adaptive change. Whether it is a beneﬁcial response (e.g.
to reduce metabolic rate) or a maladaptive response (with potential beneﬁt from TH replacement
therapy) has been much debated, but compelling evidence for the use of T3 or T4 therapy in the
majority of patients with NTI is currently lacking [11].
Changes in TH (especially T3) and TSH may be seen as early as 24 h after the onset of non-
thyroidal illness [12], and have been observed in subjects with poor nutrition/starvation, sepsis,
burns, malignancy, myocardial infarction, post-surgery, and with chronic liver and renal disease
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with progression or resolution of the underlying primary disorder (Fig. 2). Many commercial as-
says for free TH typically return low (or low-normal) FT4 and FT3, with normal or low (but rarely
fully suppressed) TSH [15,16]. However, elevated FT4 may also be found, and it is not uncommon
for the same sample to yield markedly discordant FT4 concentrations when run on different assay
platforms, reﬂecting methodological differences/limitations [14,16]. Where total TH concentrations
are measured, reductions in TT4, and in particular TT3, are common even in mild NTI, and are
usually more marked than the corresponding decreases in free hormone concentrations (likely
reﬂecting reduced serum TH binding capacity in acute and chronically ill patients, secondary to a
fall in TH binding protein concentrations and/or impaired T4/T3 binding) [14]. The magnitude of T4
decrease has been reported to correlate with a less favourable outcome [17], and mortality can be
as high as 80% when TT4 drops below 26 nmol/L [18]. When measured, reverse T3 (rT3) is usually
raised.
In subjects with acute, major psychiatric illness, raised T4 with non-suppressed TSH is sometimes
observed, but usually resolves spontaneously within a short time frame (<2weeks); in others, TSHmay
be elevated or suppressed but without accompanying abnormalities of T4 or T3 [19].
There remains considerable debate regarding the precise mechanisms underpinning NTI, with
changes noted at all levels in the pathway of TH synthesis/secretion, transport, cellular uptake and
action [14]. These include, but are not restricted to: reduced hypothalamic TRH secretion from para-
ventricular nuclei [20]; impaired pituitary TSH secretion; decreased TH binding capacity in serum [21];
reduced tissue/cellular uptake of T4 and T3; altered deiodinase activity with reduced DIO1, but
increased DIO2 and DIO3 (although ﬁndings in DIO3 knockout and DIO1/DIO2 knockout mice suggest
altered deiodinase activity may be a consequence, rather than a cause, of the changes that occur in T4
and T3) [22,23]; and altered thyroid hormone receptor expression/signalling (e.g. reduced in skeletal
muscle) [24].
The mediators of such changes are also much debated, but pro-inﬂammatory cytokines (including
IL-1, IL-6, TNF-a) have been implicated in NTI in a variety of infectious, inﬂammatory and neoplastic
states [14,25]. In addition, the reduction in leptin levels that accompanies malnutrition may directly
impair hypothalamic TRH secretion [14]. A role for excess endogenous glucocorticoids has also been
postulated, while the use of exogenous corticosteroid therapy and dopamine (see below) in critically ill
patients may further suppress pituitary TSH release.
During recovery from intercurrent illness, TH and TSH concentrations return to normal, although in
some patients TSH may become overtly elevated for a short period of time. This rise in TSH typically
precedes the increase in T4 and T3 concentrations, suggesting that it is required for the restoration of
euthyroidism [26]. It is important to be aware of this transient phenomenon in order to avoid inap-
propriate diagnosis and treatment.Pregnancy
Pregnancy has a signiﬁcant impact on HPT physiology and may be associated with marked changes
in serum thyroid hormone and thyrotropin concentrations [27]. Under normal circumstances, about
two thirds of circulating T4 is bound to TBG. During pregnancy TBG levels rise as a consequence of
oestrogen-induced increased hepatic synthesis, together with reduced degradation. Accordingly,
serum total T4 and T3 concentrations increase to approximately 150% of non-pregnant values – this
occurs during the ﬁrst half of pregnancy and is maintained thereafter until parturition. Free T4 con-
centrations also change during pregnancy: in the ﬁrst trimester a transient rise is often observed and
has been ascribed to the stimulatory effects of high circulating levels of human chorionic gonadotro-
phin (hCG) acting on the TSH receptor (TSH concentrations are correspondingly reduced, or even
partially suppressed). In its most extreme form (hyperemesis gravidarum), affected women may
become overtly thyrotoxic with a fully suppressed TSH. In this setting, it is important to distinguish
gestational hyperthyroidism from other common causes of thyrotoxicosis (e.g. Graves’ disease) as the
management of these conditions differs signiﬁcantly [28]. Measurement of anti-TSH receptor antibody
(TRAb) titres can be particularly helpful.
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than the result of analytical interference [29]. FT4 concentrations are often lower than those
observed in the non-pregnant state, which may lead to concern regarding the possibility of central
thyroid dysfunction if values are compared with non-pregnant reference ranges. Changes in FT3
broadly parallel those of FT4. TSH levels are restored as hCG levels fall in the second and third
trimester.
In addition to the effects of ﬂuctuating hCG levels and rising TBG, a number of other mechanisms
have been proposed to contribute to the alterations in thyroid status observed in pregnancy, including
an increased circulating plasma volume, enhanced DIO3 activity (placental origin: increased T4 & T3
degradation) and increased urinary iodine clearance (leading to goitre in iodine-deﬁcient regions) [27].Levothyroxine therapy
Although clinical and biochemical euthyroidism is readily restored in the majority of patients
treatedwith levothyroxine (L-T4), an important subgroupmanifests apparently anomalous TFTs, which
can be a source of considerable frustration and confusion both for patient and clinician alike. [30] Table
2 summarizes the common causes and suggested approaches for investigation of anomalous TFTs in
patients receiving L-T4 therapy.
Even after careful consideration of all of these factors, discrimination between an as yet unidentiﬁed
cause of true thyroxine malabsorption and poor L-T4 compliance can prove difﬁcult. In these cir-
cumstances, a formal thyroxine absorption test may help resolve the issue [31]. A suggested protocol
that combines both acute (6 h) and longer-term (6 week) supervised administration is shown in Fig. 3.Drug therapy
An array of commonly prescribed drugs may result in altered thyroid function/status, either by
modulating the HPT axis itself, or through downstream effects on thyroid hormone transport or
metabolism [32,33].
HPT axis
Commonly prescribed medications that are capable of altering pituitary TSH or thyroidal T4 and T3
synthesis/secretion are shown in Table 3.
Altered TBG concentrations
In subjects with an intact HPT axis, drugs affecting TBG synthesis typically result in changes in total
but not free serum thyroid hormone concentrations, although transient alterations in FT4 and FT3
have occasionally been observed [34]. Also, extreme changes in TBG concentrations can potentially
affect some FT4 assays (Moran, Gurnell, Halsall & Chatterjee, unpublished observation). It is important
to note that in patients on ﬁxed dose L-T4 therapy, an increase or decrease in the total number of
serum T4 and T3 binding sites necessitate an adjustment in levothyroxine dosage to maintain
euthyroidism.
Drugs that are recognised to increase serum TBG concentrations include oral (but not transdermal)
oestrogen, raloxifene, tamoxifen, mitotane, ﬂuorouracil, methadone and heroin. In contrast, androgens,
chronic glucocorticoid therapy and nicotinic acid have all been shown to inhibit TBG synthesis.
T4 and T3 displacement from TH binding proteins
In contrast to the situation described above, where quantitative changes in binding proteins bring
about changes in total but not free TH concentrations, the presence of agents in serum that are capable
of displacing T4 and T3 from their binding sites can alter hormone delivery and clearance and distort
diagnostic tests for FT4 and FT3. A number of commonly prescribed drugs have been shown to bring
about competition for TH binding sites on TBG, albumin and transthyretin, including furosemide
(especially with doses >80 mg/day and when given intravenously) [35] aspirin, nonsteroidal anti-
inﬂammatory agents, phenytoin and heparin [36].
Table 2
Causes of anomalous TFTs in patients receiving levothyroxine therapy [30,63].
TFT patterns/LT4 dosage
requirements
Cause Explanation
A. Normal TSH, mildly [FT4; (
higher than predicted L-T4
requirementsa)
Normal
physiological
variant
To abolish symptoms and normalise TSH concentrations,
some individuals exhibit mildly elevated FT4 (possibly
reﬂecting less efﬁcient deiodination of T4 to T3); FT3 is
typically normal
B. [TSH, low normal or YFT4;
(Requirement for high L-T4
dosages to normalise TSHa)
(i)
Maladministration
Patients should be advised to take L-T4 on an empty
stomach; certain foodstuffs (e.g. ﬁbre, espresso coffee) and
some medications (e.g. iron, calcium, PPIs, sucralfate,
aluminium hydroxide, cholestyramine, colestipol) may
impair L-T4 absorption
(ii) Malabsorption
syndromes
L-T4 malabsorption occurs with coeliac disease,
achlorhydria, lactose intolerance (lactose is a constituent of
some L-T4 preparations)
(iii) Increased TH
metabolism or
excretion
Phenytoin, carbamazepine, phenobarbitone, rifampicin and
some tyrosine kinase inhibitors (e.g. Imatinib) increase L-T4
requirements by enhancing hepatic metabolism of TH;
occasional cases of increased urinary TH loss complicating
nephrotic syndrome have also been reported
(iv) Increased TH
binding capacity
Oral oestrogen therapy or gonadotrophin-induced rise in
oestrogen concentrations (e.g. IVF treatment) results in a
marked increase in TBG and hence TH binding capacity,
necessitating an increase in L-T4 therapy; similar effects are
seen with SERMs and mitotane
C. Unexpected change in L-T4
dosage requirements to maintain
clinical and biochemical
euthyroidism
Change in LT4
preparation
Not all L-T4 preparations are of comparable potency/
bioavailability; changes in preparation are generally best
avoided but, if necessary, should prompt more frequent TFT
monitoringb
D. [TSH, normal FT4 TSH assay
interference
Heterophilic antibody interference in the TSH assay may
yield falsely elevated results; FT3 is normal
E. Persistent [TSH, with Y, [ or
normal FT4, despite treatment
with high L-T4 dosages
Poor compliance Owing to their differing half-lives, intermittent thyroxine
ingestion may result in normal or even elevated TH
concentrations, but fails to normalize TSH
F. Supraphysiologic L-T4 required to
normalise TSH, but with
resultant [FT4 (and [FT3)
Resistance to
thyroid hormone
Typically seen following inappropriate thyroid ablation or
concomitant primary hypothyroidism in a patient
harbouring a mutation in the human thyroid hormone
receptor b (THRB) gene
Key: FT4, free thyroxine; FT3, free triiodothyronine; L-T4, levothyroxine; PPI, proton pump inhibitor; SERMs, selective oestrogen
receptor modulators; TFTs, thyroid function tests; TH, thyroid hormone; TSH, thyroid stimulating hormone/thyrotropin.
a In athyreotic individuals total daily levothyroxine requirements can be estimated based on body weight and usually fall in
the range 1.6–2.0 mcg/kg (NB: the elderly typically require lower dosages, and caution must be exercised when commencing
treatment in those with conﬁrmed/suspected ischaemic heart disease or arrhythmias).
b The UK Medicines and Healthcare products Regulatory Agency (MHRA) have recently suspended one preparation of levo-
thyroxine following discovery that it yielded variable control [64].
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increasingly widespread use of lowmolecular weight heparin thromboprophylaxis in modern medical
and surgical practice. The potential for heparin to raise free TH concentrations was ﬁrst noticed by
Schatz and colleagues in 12 patients undergoing haemodialysis [37]. To investigate this further, they
administered intravenous heparin to nine healthy controls and ﬁve subjects with hypothyroidism, and
were able to show a prompt (within 2–15min) rise (up to ﬁve-fold) in FT4 concentrations, which could
not be replicated by adding a similar concentration of heparin to the sample in vitro, thus conﬁrming
that this phenomenon is initiated in vivo [37].
Subsequent studies have shown that in heparin-treated subjects, serum non-esteriﬁed fatty acid
(NEFA) concentrations may increase markedly as a consequence of heparin-induced activation of
endothelial lipoprotein lipase in vivo, leading to increased NEFA generation in vitro during sample
storage or incubation. In the presence of normal serum albumin concentrations, NEFA concentrations
>2–3 mmol/L exceed normal serum binding capacity, resulting in direct competition for T4 and T3
binding sites on TBG either by NEFAs themselves or as a result of displacement of other ligands from the
Fig. 3. Protocol for supervised thyroxine absorption test, followed by weekly supervised thyroxine administration. Key: ECG,
electrocardiogram; FT4, free thyroxine; FT3, free triiodothyronine; TSH, thyrotropin (thyroid stimulating hormone).
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pronounced when serum triglyceride concentrations are elevated, in the presence of hypo-
albuminaemia, and with laboratory methods that require long incubation periods [40]. Indeed, in the
presence of sufﬁcient triglyceride substrate, even very low dose intravenous heparin (equivalent to that
used to maintain the patency of an indwelling cannula), and subcutaneous low molecular weight
heparin (LMWH) prophylaxis can lead to FT4 (and FT3) elevation. Moreover, the heparin effect has
been observedwith a variety of assay platforms including equilibrium dialysis, ultracentrifugation, and
direct immunoassay [41].
Ideally therefore, measurement of FT4 and FT3 is best avoided in patients receiving heparin therapy.
However, when indicated, taking a blood sample more than 10 h after the last injection of heparin, and
analysing it without delay, can help reduce the risk of artifactual hyperthyroxinaemia, although cli-
nicians should bear in mind that small rises in free TH may be inevitable in predisposed individuals
[41]. Alternatively, measurement of total TH levels, together with TSH and TBG [36], can help conﬁrm
the patient’s euthyroid status when displacement is suspected [42].Assay interference
TSH measurement
Most commercially available TSH assays are based on an immunometric two-site (or ‘sandwich’)
format with capture and (labelled) detection antibodies directed against different epitopes on TSH,
with the analyte essentially acting as a bridge between the two (Fig. 4a). The capture antibody is
Table 3
Examples of drugs directly affecting pituitary TSH or thyroidal T4 & T3 secretion in previously euthyroid subjects.
TFT patterns Comments
Drugs affecting
thyroid hormone
secretion
Iodide 1. [TSH, YFT4 Inorganic iodide (dietary/supplements) as well as iodine
containing organic compounds (e.g. radiological contrast
agents) can cause a transient disturbance of thyroid
function; patients with diminished thyroid reserve (e.g.
chronic autoimmune thyroiditis) are at risk of developing
persistent hypothyroidism.
2. YTSH, [FT4 Individuals with latent/low-grade thyroid autonomy (e.g. in
a pre-existing MNG) may develop overt hyperthyroidism
following exposure to iodine-containing compounds (Jod-
Basedow effect), which may persist for months
Amiodarone 1. Transient [TSH;
[FT4, normal FT3
Short-lived rises in TSH are common during the ﬁrst few
months of treatment with amiodarone; inhibition of type 1
DIO leads to persistent elevation of FT4, but normal FT3
2. YTSH, [FT4 Two main types of thyrotoxicosis are recognised: type 1
(large iodine load precipitating latent thyroid autonomy);
type 2 (destructive thyroiditis); amiodarone inhibits
T4/ T3 conversion such that T4 is typically more markedly
elevated than T3
3. [TSH, YFT4 Hypothyroidism occurs in up to 15% of patients (particularly
women and those with positive antithyroid antibodies); it
may reﬂect failure to escape from theWolff–Chaikoff effecta
Lithium 1. [TSH, Y or normal
FT4
Overt or subclinical hypothyroidism
2. YTSH, [FT4 Thyroiditis occurs in a small number of patients and is
typically self-limiting
TKIs 1. [TSH, YFT4 Primary hypothyroidism (possibly due to a direct toxic
effect on the thyroid gland) has been observed with some
TKIs, e.g. Sunitinib, Sorafenib
2. YTSH, [FT4 A prodromal thyrotoxic phase is occasionally seen in
patients receiving Sunitinib
Immune
modulators
1. YTSH, [FT4 Graves’ disease has been reported in patients receiving: (i)
Alemtuzumab (a humanised monoclonal antibody directed
against CD52) for multiple sclerosis; (ii) HAART for HIV
infection; (iii) INFa for chronic hepatitis C
2. [TSH, YFT4 Hashimoto’s thyroiditis may complicate INFa therapy (
prodromal thyrotoxic phase)
Drugs affecting TSH
secretion
Dopamine
agonists
YTSH (often transient),
/ (or mild Y) FT4
Intravenous infusion of dopamine or oral dopamine agonist
therapy can suppress TSH secretion via activation of D2
receptors on pituitary thyrotrophs; however, clinically
relevant central hypothyroidism does not usually occur,
although some studies have suggested that dopamine
infusion in a critically ill subject with concomitant NTI may
result in genuine hypothyroidism
Glucocorticoids YTSH (often transient),
/ (or mild Y) FT4
Glucocorticoid-mediated inhibition of hypothalamic TRH
synthesis/release (acting via glucocorticoid receptors in the
paraventricular nucleus) results in reduced pituitary TSH
secretion; however, chronic hypercortisolism (endogenous
or exogenous) is not generally associated with clinically
signiﬁcant central hypothyroidism
Somatostatin
analogues
YTSH (often transient),
/(or mild Y) FT4
Both octreotide and lanreotide suppress pituitary TSH
secretion through a direct inhibitory action on pituitary
thyrotrophs; however, this effect is usually transient and
not associated with clinically signiﬁcant central
hypothyroidism
Rexinoids YTSH, YFT4 Bexarotene (Targretin) has been linked to the
development of biochemical and, in a signiﬁcant proportion
of patients, clinical hypothyroidism when used to treat
patients with cutaneous T-cell lymphoma; inhibition of
TSHb transcription leads to decreased TSH production;
additional effects on TH metabolism (deiodination,
sulphation) have also been reported
O. Koulouri et al. / Best Practice & Research Clinical Endocrinology & Metabolism 27 (2013) 745–762754
Table 3 (continued )
TFT patterns Comments
Metformin YTSH,/FT4 Several observational studies have reported an apparent
TSH lowering effect of metformin therapy in patients with
diabetes; however, whether this effect is limited to those
with pre-existing disorders of the HPT axis, especially
subjects with an elevated TSH (reﬂecting central activation
of the axis) remains unclear, and further studies are
required
Key: D2, dopamine D2 receptors; DIO, deiodinase; FT4, free thyroxine; FT3, free triiodothyronine; HAART, highly active anti-
retroviral therapy; INFa, interferon alpha; NTI, non-thyroidal illness; T4, thyroxine; T3, triiodothyronine; TFTs, thyroid function
tests; TKIs, tyrosine kinase inhibitors; TSH, thyroid stimulating hormone/thyrotropin; TSHb, beta subunit of TSH. Adapted with
permission from: Koulouri O, Gurnell M. How to interpret thyroid function tests. Clin Med 2013; 13:282–6. Copyright  2013
Royal College of Physicians.
a Wolff–Chaikoff effect ¼ impairment of T4 and T3 synthesis by high intrathyroidal concentrations of iodine.
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thus increasing sensitivity; often, several different detection antibodies are employed to further
improve assay sensitivity. The presence of human anti-animal antibodies (HAAs) in a patient’s serum
can interfere with TSH measurement if directed against the same species as the assay antibodies: thus,
a HAA that is capable of cross-linking the capture and detection antibodies may cause ‘positive
interference’, leading to a falsely high TSH (Fig. 4b); conversely, a HAA that blocks TSH binding to either
capture or detection antibodies will result in ‘negative interference’, causing a falsely low TSH readoutFig. 4. Schematic representation of an immunoradiometric assay for measurement of serum TSH. a. TSH is bound by both capture
(immobilised) and detection (labelled) antibodies. b. The presence of a human anti-animal (HAA) or heterophilic antibody that is
capable of cross-linking the capture and detection antibodies even in the absence of analyte (TSH), results in positive assay inter-
ference. c. In contrast, an HAA or heterophilic antibody that binds either the capture or detection antibody to prevent crosslinking
(even in the presence of TSH) results in negative assay interference.
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animals in an attempt to ‘mop up’ HAAs. However, heterophile antibodies (which are weak, poly-
speciﬁc antibodies that are similarly capable of causing negative or positive interference) can prove
more difﬁcult to remove. Such interference in the TSH assaymay be seen in cases of Graves’ disease and
in patients with positive rheumatoid factor (RhF), although emerging evidence suggests that the
ﬁnding of a raised RhF titre in this context may in itself reﬂect heterophilic antibody interference in the
RhF assay (Chatterjee, Halsall & Gurnell, unpublished data). Interfering antibodies can also bind the
analyte (TSH) rather than the assay antibodies. An extreme example of this type of interference is the
‘macro hormone’ complex, in which a speciﬁc anti-TSH immunoglobulin binds TSH and neutralizes its
biological activity, but leaves epitopes exposed for interaction with the assay antibodies. The conse-
quence is analogous to artefactually elevated prolactin concentrations seen in patients with macro-
prolactinaemia. If interference is suspected, it is best to seek the advice of the laboratory as there are
several ways to conﬁrm this, for example by demonstrating:
 varying TSH results in assays that utilize different antibody pairs or incubation times,
 a different TSH result following manoeuvres [using polyethylene glycol (PEG) or protein G/A
treatment of sample] that remove the interfering antibody,
 nonlinear TSH measurement following sample dilution: if either TSH or the assay reagents are
weakly bound by interfering antibodies this interaction may be disrupted by dilution and a
nonlinear dilution series will result.Free T4/T3 measurement
Determination of FT4 (and FT3) is particularly challenging as the assay must detect very low con-
centrations of ‘free’ hormone relative to a vast excess of protein-bound analyte (>99.5%). The relatively
small size of T4 (and T3) precludes use of a two-site assay format, so ‘competition assays’ are used;
here, T4 in the serum competes with labelled T4 analogue for a ﬁxed number of anti-T4 antibody
binding sites or with an immobilized T4 analogue for a labelled anti-T4 antibody [43]. Free hormone
assays are designed such that the equilibrium between T4 and its binding proteins is preserved during
measurement, so that the amount of tracer displaced reﬂects the ‘free’ rather than ‘total’ hormone
concentration. Clearly, the presence of factors in serum which affect this equilibrium will confound
hormone measurement. Examples include:
 fractionated or unfractionated heparin and other displacing agents (see above)
 anti-iodothyronine antibodies, which can bind the tracer
 HAAs or heterophile antibodies that block the assay antibody
 variant thyroid hormone binding proteins [e.g. albumin in familial dysalbuminaemic hyper-
thyroxinaemia (FDH)] with altered afﬁnity for T4
The use of a ‘two-step’ (‘back titration’) assaymethod, with awash step prior to tracer addition, may
reduce but not completelyeliminate interference. If erroneousTH results are suspectedwith a ‘one-step’
assay, then re-measurement using a ‘two-step’ assay is a logical ﬁrst step. If the problem persists, hor-
mone measurement following equilibrium dialysis (ED) remains the gold-standard for eliminating FT4
assay interference,with the caveat that thismethodwill notdetect displacing agents, as discussedabove.Distinguishing resistance to thyroid hormone (TRb RTH) from a TSH-secreting pituitary tumour
(TSHoma)
Amongst the various discordant TFT patterns shown in Fig. 2, one of the most challenging dis-
tinctions to make is between resistance to thyroid hormone due to a loss-of-function mutation in the
human THRB gene (TRb RTH) [6] and a TSH-secreting pituitary adenoma (TSHoma/thyrotropinoma)
[44].
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TRb RTH has an estimated incidence of 1 in 40–50,000 live births [6]. Thyrotropinomas are
considered to be the rarest of the classical pituitary tumours, accounting for less than 2% of all ade-
nomas, and with an estimated prevalence of 1 case per million population [44–46]. However, a recent
report suggests that this historical ﬁgure may be changing (increasing 2–3 fold), as a consequence of
increasing awareness among clinicians, coupled with the greater combination screening with T4 (T3)
and ultrasensitive TSH assays, and increased availability of high resolution pituitary imaging [47].
Clinical features
The clinical phenotype of both disorders overlaps signiﬁcantly, ranging from apparently asymp-
tomatic individuals, through to those with more overt manifestations of thyrotoxicosis (in particular
arrhythmias) and goitre. In TRb RTH, a subgroup of patients with predominant central/pituitary
resistance are particularly prone to developing thyrotoxic symptoms and signs [6]. In both contexts, a
previous history of inappropriate attempts at thyroid ablation (on the basis of misdiagnosed primary
hyperthyroidism) is a relatively frequent ﬁnding. Accordingly, it is not usually possible to distinguish
between the two conditions based on clinical ﬁndings alone.
T4, T3 and TSH concentrations
The degree of hyperthyroxinaemia is comparable in both conditions [46], although there may be a
tendency to higher (albeit overlapping) TSH concentrations in TSHomas (Koulouri, Moran, Halsall,
Chatterjee & Gurnell, unpublished observation). Concomitant common thyroid dysfunction can
modulate the degree of hyperthyroxinaemia in both disorders; thus, several cases of TRb RTH or
TSHoma with coexistent Hashimoto’s thyroiditis have been reported, with lower than expected FT4
and FT3 concentrations (sometimes even within the reference range), with the underlying central
diagnosis being suspected on the basis of inability to suppress TSH despite levothyroxine therapy in
supraphysiologic dosage [48,49].
Other biochemical and dynamic tests
Raised serum concentrations of pituitary glycoprotein hormone a-subunit (ASU) are associated
with TSHomas [44,46], but are also recorded in non-functioning and GH-secreting pituitary tumours.
Furthermore, normal ASU concentrations, but an elevated ASU/TSHmolar ratio (>1.0), are a recognized
ﬁnding in TSH-secreting microadenomas; however, the latter needs careful interpretationwith clinical
context – elevated molar ratios are also seen in some normal subjects, especially postmenopausal
women.
A number of peripheral tissue markers of thyroid hormone action have been proposed to aid
discrimination between TRb RTH and TSHoma, with serum SHBG (analysed using age- and gender-
speciﬁc reference ranges) reported to be the most discriminatory [44]. However, the utility of such
markers is limited by their lack of speciﬁcity, especially when measured in the basal state. For
example, SHBG concentrations are known to be affected by several factors including exogenous
oestrogen therapy, liver dysfunction, insulin resistance, obesity and increased growth hormone
(which is co-secreted in about 18% of TSHomas [44]). Dynamic testing with measurement of tissue
biomarkers and the TSH responsiveness to TRH, before and after administration of liothyronine (the
‘T3 suppression test’) may be more discriminatory [44–46], although there is a relative paucity of
generalizable reference data for both normal controls and subjects with RTH and TSHoma. In addi-
tion, the need to limit its use to younger patients without coexistent cardiac disease further limits its
utility.
In contrast, assessment of the TSH response to intravenous TRH (200 mg), with sampling at 20
and 60 min post-injection, is a relatively easy and safe test to perform, and may offer good
discriminatory power in distinguishing TRb RTH from TSHoma. A less than 1.5-fold rise in TSH is
strongly suggestive of the presence of TSHoma [44] and occurs in the majority (80–90%) of
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still attenuated and readily distinguished from the more exuberant TSH response of TRb RTH pa-
tients (typically greater than 5-fold, Koulouri, Moran, Halsall, Chatterjee and Gurnell, unpublished
observation).Pituitary imaging
The presence of an obvious lesion on pituitary imaging (especially a macroadenoma) favours the
diagnosis of TSHoma, although the possibility of RTHwith a concomitant incidentalomamust be borne
in mind. In addition, an increasing proportion of microTSHomas, some of which are not readily
visualised on conventional MRI, are being recognised, and dynamicMRI and/or functional imagingmay
be required to visualise these [44,45]. A further confounder is that persistently elevated TSH concen-
trations, either in the context of chronic non-compliance in primary hypothyroidism or following
thyroid ablation in TRb RTH, results in thyrotroph hyperplasia and pituitary enlargement which is
reversible. [50]Trial of somatostatin receptor ligand (SRL) therapy
Most TSHomas (90%) respond well to long-acting SRL therapy, with signiﬁcant reductions in, and
often normalization of, FT4 and FT3 concentrations after a two month trial [51]. In contrast, subjects
with TRb RTH do not show any signiﬁcant change in FT4 and FT3 in response to depot SRL.Genetics of THRB RTH
Approximately 80% of TRb RTH cases are dominantly inherited, with the remainder occurring
sporadically due to ‘de novo’ mutations [52]. Therefore, similarly abnormal TFTs in ﬁrst-degree rel-
atives strongly suggests RTH. THRB gene sequencing conﬁrms the diagnosis in 85% of cases, but 15%
are not associated with identiﬁable THRBmutations, such that absence of an abnormality in this gene
does not exclude the diagnosis [52]. In addition, the recent identiﬁcation of a non-pathological
sequence variant in THRB in a kindred with primary autoimmune thyroid disease serves as a
timely reminder that close correlation of clinical and genetic ﬁndings is mandatory in all cases of
suspected RTH [53].
Other genetic disorders of TH transport, metabolism or action
MCT8 mutations
An X-linked disorder (Allan–Herndon–Dudley syndrome) of childhood-onset, with psychomotor
retardation including speech and developmental delay and spastic quadriplegia, is caused by defects in
theMCT8 (SLC16A2) gene, encoding amembrane transporter. In addition to neurological abnormalities,
male patients exhibit a characteristic pattern of abnormal TFTs with elevated FT3, low FT4 and normal
TSH concentrations [6,54,55].Functional deiodinase deﬁciency
The deiodinase enzymes are part of a larger family of 25 human proteins containing selenocysteine.
Recently, a multisystem selenoprotein deﬁciency disorder, manifesting with growth retardation in
childhood or other features (male infertility, skeletal myopathy, photosensitivity, hearing loss) has
been described and is associated with a characteristic thyroid hormone signature (raised FT4, normal/
low FT3 and normal TSH concentrations), due to functional DIO deﬁciencies [6,56,57].
Fig. 5. Algorithm for the interpretation of discordant TFTs. Key: FT3, free triiodothyronine; FT4, free thyroxine; HPT, hypothalamic–
pituitary–thyroid; RR, reference range; TFTs, thyroid function tests; TH, thyroid hormones; L-T4, levothyroxine; NTI, non-thyroidal
illness, TT4, total thyroxine; TT3, total triiodothyronine; TSH, thyroid stimulating hormone (thyrotropin); TH, thyroid hormones;
TBG, thyroxine binding globulin.
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In contrast to TRb RTH, mutations in human TRa1 mediate RTH with features of hypothyroidism in a
different subset of tissues (e.g. CNS, gastrointestinal tract, myocardium, skeletal muscle, skeleton), but are
not associated with a markedly dysregulated pituitary–thyroid axis. To date only four individuals har-
bouring such mutations have been reported. Clinical features include growth and developmental retar-
dation, skeletal dysplasia and constipation associated with low-normal T4 and high-normal T3
concentrations (resulting ina lowT4:T3 ratio), togetherwith subnormal reverseT3; TSH isnormal [58–60].Summary
Although most thyroid function test patterns are easy to interpret, and concordant with
clinical assessment of thyroid status, a small but important subset of patients exhibit results that are either
discordantwith the clinical picture or not congruentwith each other. In such cases, a structured approach
to further assessment is essential to avoid unnecessary/inappropriate investigation and treatment. Once
confounding inﬂuences [e.g. physiological changes of age, pregnancy, intercurrent (non-thyroidal) illness
orconcomitantmedicationuse]havebeenexcluded, close liaisonwith theclinicalbiochemistry laboratory
is required to systematically exclude thyroid hormone and TSH assay interference. Only then should
further investigation for rare acquired and genetic causes of anomalous/discordant TFTs be considered.
An algorithm summarizing this approach to investigation and differential diagnosis is shown in Fig. 5.
O. Koulouri et al. / Best Practice & Research Clinical Endocrinology & Metabolism 27 (2013) 745–762760Disclosures
None of the authors have anything to disclose.Practice points
 Knowledge of hypothalamic–pituitary–thyroid axis physiology, the factors governing TH
action at a tissue/cellular level, and the different patterns of TFTs that may be encountered in
clinical practice, is central to establishing the correct diagnosis when clinical features and TFT
results appear discordant/incongruous.
 Reappraisal of the clinical context – in particular exclusion of confounding intercurrent illness
or medication usage, coupled with reassessment of thyroid status – should be the ﬁrst step to
resolving such cases.
 Targeted investigation to deﬁnitively exclude assay interference may require specialist lab-
oratory input.
 Genetic and acquired disorders of the HPT axis are rare, but should be considered if all other
steps have failed to identify a cause for anomalous/discordant TFTs.
Research agenda
 Age, gender and pregnancy-speciﬁc reference ranges for commonly used T4, T3 and TSH
immunoassay platforms are urgently required. Also, harmonization of TFT assays in routine
clinical practice will simplify data interpretation. [61]
 The development and validation of mass spectrometry assays for free TH measurement
should provide an additional useful laboratory tool to exclude immunoassay interference.
[62]
 The identiﬁcation of better markers of TH action in different tissues is necessary to enable
diagnosis of disorders with subtle HPT axis dysfunction and to guide treatment, especially in
the context of central hypo- or hyper-thyroidism.
 Increasing availability of next generation sequencing will likely expand the repertoire of
genetic causes of abnormalities of the HPT axis and disorders of TH transport, metabolism
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